Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase 2/3 next year in neurogenic detrusor overactivity.
Philippe Chambon, Cyllene Therapeutics CEO
July 7, 2026 01:30 AM EDT
FinancingStartupsCell/Gene Tx
French gene therapy biotech gets €33M to follow Krystal's blueprint
Kyle LaHucik
The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment…
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen,…
Crystalys Therapeutics raises $130M Series B, led by Frazier Life Sciences, to bring gout drug dotinurad to US/EU markets. The…
Genentech builds $750M OR facility; Bavarian Nordic delays Lyme vaccine to 2028; Xspray gets 2nd CRL for Dasynoc over NerPharMa…
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
